1 – 50 of 56
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort
(
- Contribution to journal › Article
- 2020
-
Mark
Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB
(
- Contribution to journal › Article
- 2016
-
Mark
Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections
(
- Contribution to journal › Article
-
Mark
Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
(
- Contribution to journal › Article
-
Mark
Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies
(
- Contribution to journal › Article
- 2015
-
Mark
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
(
- Contribution to journal › Article
- 2014
-
Mark
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a In-111-radiolabelled monoclonal antibody, 11B6
(
- Contribution to journal › Article
-
Mark
Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens.
(
- Contribution to journal › Article
- 2013
-
Mark
Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens
(
- Contribution to journal › Article
-
Mark
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
(
- Contribution to journal › Article
- 2012
-
Mark
Quantification of cystatin C by time-resolved fluorometry-based immunoassays
(
- Contribution to journal › Article
-
Mark
Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function
(
- Contribution to journal › Article
-
Mark
Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome
(
- Contribution to journal › Article
-
Mark
Targeting the human kallikrein-2 (hK2) expression in prostate cancer using 111In-labelled monoclonal antibody 11B6
2012) p.1102-1102(
- Contribution to conference › Abstract
-
Mark
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
(
- Contribution to journal › Article
-
Mark
Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations.
2012) In Journal of the National Cancer Institute(
- Contribution to journal › Article
- 2011
-
Mark
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(145) or Lys(146) from fPSA without internal cleavages at Lys(145) or Lys(146)
(
- Contribution to journal › Article
-
Mark
A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening
(
- Contribution to journal › Article
- 2010
-
Mark
Dry-Reagent Double-Monoclonal Assay for Cystatin C
(
- Contribution to journal › Article
-
Mark
Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication.
(
- Contribution to journal › Article
-
Mark
Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
(
- Contribution to journal › Article
-
Mark
A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
(
- Contribution to journal › Article
- 2009
-
Mark
FGF-8b Induces Growth and Rich Vascularization in an Orthotopic PC-3 Model of Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy
(
- Contribution to journal › Article
-
Mark
Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort
(
- Contribution to journal › Article
-
Mark
Circulating prostate tumor cells detected by Reverse transcription-PCR in men with localized or castration-refractory prostate cancer : Concordance with CellSearch assay and association with bone metastases and with survival
(
- Contribution to journal › Article
- 2008
-
Mark
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
(
- Contribution to journal › Article
- 2007
-
Mark
Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women
(
- Contribution to journal › Article
-
Mark
Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood
(
- Contribution to journal › Article
-
Mark
Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer
(
- Contribution to journal › Article
- 2006
-
Mark
Intact Free Prostate-Specific Antigen and Free and Total Human Glandular Kallikrein 2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to F(ab')(2) Fragments.
(
- Contribution to journal › Article
- 2005
-
Mark
Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis.
(
- Contribution to journal › Article
-
Mark
Biochemical markers of bone turnover are influenced by recently sustained fracture.
(
- Contribution to journal › Article
-
Mark
Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy
(
- Contribution to journal › Article
- 2004
-
Mark
Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro
(
- Contribution to journal › Article
-
Mark
Serum estradiol, testosterone, and sex hormone-binding globulin as regulators of peak bone mass and bone turnover rate in young Finnish men
(
- Contribution to journal › Article
-
Mark
Biochemical markers of bone metabolism and prediction of fracture in elderly women.
(
- Contribution to journal › Article
- 2003
-
Mark
Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
(
- Contribution to journal › Article
-
Mark
Standardization of Two Immunoassays for Human Glandular Kallikrein 2.
(
- Contribution to journal › Article
- 2002
-
Mark
Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
(
- Contribution to journal › Article
- 2001
-
Mark
Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146
(
- Contribution to journal › Article
-
Mark
Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients
(
- Contribution to journal › Article
-
Mark
Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing
(
- Contribution to journal › Article
-
Mark
Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml
(
- Contribution to journal › Article
- 2000
-
Mark
Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections
(
- Contribution to journal › Article
- 1999
-
Mark
Time-resolved fluorescence in immunocytochemical detection of prostate-specific antigen in prostatic tissue sections
(
- Contribution to journal › Article
- 1998
-
Mark
Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum
(
- Contribution to journal › Article
- 1997
-
Mark
Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen
(
- Contribution to journal › Article
- 1996
-
Mark
Structural investigation of the alpha-1-antichymotrypsin : Prostate-specific antigen complex by comparative model building
(
- Contribution to journal › Article
-
Mark
A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates : The best case scenario
(
- Contribution to journal › Article